Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease

Current Drug Metabolism

Volumn 12, Issue 6, 2011, Pages 594-598

  Guerra, Iván ^a,c   Chaparro, María ^b   Bermejo, Fernando ^a   Gisbert, Javier P ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^c NONE   (Spain)

Author keywords

Adalimumab; Antibodies; Immunogenicity; Infliximab; Through levels; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; BINDING AFFINITY; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; ENDOSCOPY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION; NEOPLASM; NONHUMAN; PATIENT SELECTION; RADIOIMMUNOASSAY; RADIOLOGY; RHEUMATOID ARTHRITIS; SERUM; TREATMENT RESPONSE;

EID: 79957956645     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011795713689     Document Type: Article

References (44)

1. Watts, D. A.; Satsangi, J. The genetic jigsaw of inflammatory bowel disease. Gut, 2002, 50 Suppl 3, III31-6. (Pubitemid 34407454)
2. Spoettl, T.; Hausmann, M.; Klebl, F.; Dirmeier, A.; Klump, B.; Hoffmann, J.; Herfarth, H.; Timmer, A.; Rogler, G. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm. Bowel Dis., 2007, 13(6), 727-32. (Pubitemid 46909987)
3. Bazzoni, F.; Beutler, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 1996, 334(26), 1717-25. (Pubitemid 26193625)
4. Aybay, C.; Ozel, S. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol. Int., 2006, 26(5), 473-80.
5. Wong, M.; Ziring, D.; Korin, Y.; Desai, S.; Kim, S.; Lin, J.; Gjertson, D.; Braun, J.; Reed, E.; Singh, R. R. TNFalpha blockade in human diseases: mechanisms and future directions. Clin. Immunol., 2008, 126(2), 121-36.
6. Lee, T. W.; Fedorak, R. N. Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol. Clin. North Am., 2010, 39(3), 543-57.
7. Feldmann, M.; Maini, R. N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J.Immunol., 2010, 185(2), 791-4.
8. Papadakis, K. A.; Targan, S. R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med., 2000, 51, 289-98. (Pubitemid 30216038)
9. Mitoma, H.; Horiuchi, T.; Hatta, N.; Tsukamoto, H.; Harashima, S.; Kikuchi, Y.; Otsuka, J.; Okamura, S.; Fujita, S.; Harada, M. Infliximab induces potent anti-inflammatory responses by outsideto- inside signals through transmembrane TNF-alpha. Gastroenterology, 2005, 128(2), 376-92. (Pubitemid 40431090)
10. Scallon, B. J.; Moore, M. A.; Trinh, H.; Knight, D. M.; Ghrayeb, J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine, 1995, 7(3), 251-9.
11. Sandborn, W. J. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep., 2003, 5(6), 501-5. (Pubitemid 38915050)
12. Di Sabatino, A.; Pender, S. L.; Jackson, C. L.; Prothero, J. D.; Gordon, J. N.; Picariello, L.; Rovedatti, L.; Docena, G.; Monteleone, G.; Rampton, D. S.; Tonelli, F.; Corazza, G. R.; MacDonald, T. T. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology, 2007, 133(1), 137-49. (Pubitemid 47031137)
13. Dignass, A.; Van Assche, G.; Lindsay, J.O.; Lémann, M.; Söderholm, J.; Colombel, J.F.; Danese, S.; D'Hoore, A.; Gassull, M.; Gomollón, F.; Hommes, D.W.; Michetti, P.; O'Morain, C.; Oresland, T.; Windsor, A.; Stange, E.F.; Travis, S.P. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J. Crohns Colitis, 2010, 4(1), 28-62.
14. Afif, W.; Leighton, J. A.; Hanauer, S. B.; Loftus, E. V., Jr.; Faubion, W. A.; Pardi, D. S.; Tremaine, W. J.; Kane, S. V.; Bruining, D. H.; Cohen, R. D.; Rubin, D. T.; Hanson, K. A.; Sandborn, W. J. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm. Bowel Dis., 2009, 15(9), 1302-7.
15. Hanauer, S. B.; Feagan, B. G.; Lichtenstein, G. R.; Mayer, L. F.; Schreiber, S.; Colombel, J. F.; Rachmilewitz, D.; Wolf, D. C.; Olson, A.; Bao, W.; Rutgeerts, P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359(9317), 1541-9. (Pubitemid 34621118)
16. Hanauer, S. B.; Sandborn, W. J.; Rutgeerts, P.; Fedorak, R. N.; Lukas, M.; MacIntosh, D.; Panaccione, R.; Wolf, D.; Pollack, P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 2006, 130(2), 323-33; quiz 591.
17. Gisbert, J. P.; Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol., 2009, 104(3), 760-7.
18. Rutgeerts, P.; Vermeire, S.; Van Assche, G. Predicting the response to infliximab from trough serum levels. Gut, 2010, 59(1), 7-8.
19. Nestorov, I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum., 2005, 34(5 Suppl1), 12-8.
20. Maser, E. A.; Villela, R.; Silverberg, M. S.; Greenberg, G. R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol., 2006, 4(10), 1248-54. (Pubitemid 44512213)
21. Seow, C. H.; Newman, A.; Irwin, S. P.; Steinhart, A. H.; Silverberg, M. S.; Greenberg, G. R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut, 2010, 59(1), 49-54.
22. Reich, K.; Nestle, F. O.; Papp, K.; Ortonne, J. P.; Evans, R.; Guzzo, C.; Li, S.; Dooley, L. T.; Griffiths, C. E. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 2005, 366(9494), 1367-74. (Pubitemid 41443403)
23. St Clair, E. W.; Wagner, C. L.; Fasanmade, A. A.; Wang, B.; Schaible, T.; Kavanaugh, A.; Keystone, E. C. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46(6), 1451-9. (Pubitemid 34620190)
24. Van Moerkercke W.; Ackaert C.; Compernolle G.; Jürgens M.; Cleynen I.; Van Assche G.; Rutgeerts P.; Gils A.; Vermeire S. High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease. Gastroenterology, 2010, 138(5):S-60.
25. Baert, F.; Noman, M.; Vermeire, S.; Van Assche, G.; D'Haens G.; Carbonez, A.; Rutgeerts, P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med., 2003, 348(7), 601-8. (Pubitemid 36204954)
26. West, R. L.; Zelinkova, Z.; Wolbink, G. J.; Kuipers, E. J.; Stokkers, P. C.; van der Woude, C. J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol. Ther., 2008, 28(9), 1122-6.
27. Afif, W.; Loftus, E. V., Jr.; Faubion, W. A.; Kane, S. V.; Bruining, D. H.; Hanson, K. A.; Sandborn, W. J. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol., 2010, 105(5), 1133-9.
28. Hanauer, S. B.; Wagner, C. L.; Bala, M.; Mayer, L.; Travers, S.; Diamond, R. H.; Olson, A.; Bao, W.; Rutgeerts, P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol., 2004, 2(7), 542-53. (Pubitemid 38834038)
29. Radstake, T. R.; Svenson, M.; Eijsbouts, A. M.; van den Hoogen, F. H.; Enevold, C.; van Riel, P. L.; Bendtzen, K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis., 2009, 68(11), 1739-45.
30. Candon, S.; Mosca, A.; Ruemmele, F.; Goulet, O.; Chatenoud, L.; Cezard, J. P. Clinical and biological consequences of immunizationto infliximab in pediatric Crohn's disease. Clin. Immunol., 2006, 118(1), 11-9. (Pubitemid 43012041)
31. Cassinotti, A.; Travis, S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm. Bowel Dis., 2009, 15(8), 1264-75.
32. Farrell, R. J.; Alsahli, M.; Jeen, Y. T.; Falchuk, K. R.; Peppercorn, M. A.; Michetti, P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 2003, 124(4), 917-24. (Pubitemid 36389794)
33. Rutgeerts, P.; Sandborn, W. J.; Feagan, B. G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S. B.; Lichtenstein, G. R.; de Villiers, W. J.; Present, D.; Sands, B. E.; Colombel, J. F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353(23), 2462-76. (Pubitemid 41770166)
34. Van Assche, G.; Magdelaine-Beuzelin, C.; D'Haens, G.; Baert, F.; Noman, M.; Vermeire, S.; Ternant, D.; Watier, H.; Paintaud, G.; Rutgeerts, P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology, 2008, 134(7), 1861-8. (Pubitemid 351790744)
35. Sandborn, W. J.; Rutgeerts, P. J.; Reinisch, W.; Mantzaris, J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G. R.; Woude, C. J.; Diamond, R.; Broussard, D.; Tang, K.; Colombel, J. F. One Year Data from the Sonic Study: A Randomized, Double- Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy. Gastroenterology, 2009, 136(5), A-116.
36. Colombel, J. F.; Sandborn, W. J.; Reinisch, W.; Mantzaris, G. J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.; Diamond, R. H.; Broussard, D. L.; Tang, K. L.; van der Woude, C. J.; Rutgeerts, P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med., 2010, 362(15), 1383-95.
37. Allez, M.; Karmiris, K.; Louis, E.; Van Assche, G.; Ben-Horin, S.; Klein, A.; Van der Woude, J.; Baert, F.; Eliakim, R.; Katsanos, K.; Brynskov, J.; Steinwurz, F.; Danese, S.; Vermeire, S.; Teillaud, J. L.; Lemann, M.; Chowers, Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns Colitis, 2010, 4(4), 355-66.
38. Bendtzen, K.; Geborek, P.; Svenson, M.; Larsson, L.; Kapetanovic, M. C.; Saxne, T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum., 2006, 54(12), 3782-9. (Pubitemid 44955878)
39. Bendtzen, K.; Ainsworth, M.; Steenholdt, C.; Thomsen, O. O.; Brynskov, J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand. J. Gastroenterol., 2009, 44(7), 774-81.
40. Svenson, M.; Geborek, P.; Saxne, T.; Bendtzen, K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford), 2007, 46(12), 1828-34. (Pubitemid 350168300)
41. Wolbink, G. J.; Vis, M.; Lems, W.; Voskuyl, A. E.; de Groot, E.; Nurmohamed, M. T.; Stapel, S.; Tak, P. P.; Aarden, L.; Dijkmans, B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum., 2006, 54(3), 711-5.
42. Cheifetz, A.; Mayer, L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai. J. Med., 2005, 72(4), 250-6. (Pubitemid 41052052)
43. Wang S.L.; Ohrmund L.; Singh S. Measurement of Human Anti- Chimeric Antibodies (Haca) and Infliximab Levels in Patient Serum Using a Novel Homogeneous Assay. Gastroenterology, 2010, 138(5), S-684-5.
44. Colombel, J. F.; Sandborn, W. J.; Rutgeerts, P.; Enns, R.; Hanauer, S. B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J. D.; Pollack, P. F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007, 132(1), 52-65. (Pubitemid 46108762)